In Brief

FDA softens disclaimer for green tea QHC; Formulife/Purus covers spectrum of violations; NAD refers Schick case to FTC; Genomma drops Prestige Brands board bid.

FDA gives sunscreen makers an eleventh-hour extension to comply with new labeling and effectiveness testing requirements. The agency pushed back the deadline by six months for sunscreen products to undergo broad spectrum testing and amend label claims to reflect the test results. Firms now must test and revise packaging by Dec. 17, 2012, for all products with annual sales of $25,000 and up, and by Dec. 17, 2013, for other products, according to a notice in the May 11 Federal Register. FDA extended the deadline after the Consumer Healthcare Products Association and the Personal Care Products Council argued broad spectrum testing for all the sunscreen products would require at least 10 months due to the limited capacity of testing facilities and that complex label redesigns, such as on glass or plastic containers, would take longer than the one year the agency originally granted. Without a delay, the trade groups also argued, firms might pull their products from the market until they complied, which would result in a sunscreen shortage Also see "Industry Needs More Time To Comply With Sunscreen Testing, Labeling Rule" - Pink Sheet, 29 August, 2011..

FDA grants Fleminger Inc. a less-restrictive qualified health claim for its green tea products, following a federal court order that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

More from Geography

Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII

 

Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By 

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.